Ronald Zolty

The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the ASCEND-HF Trial

Acute decompensated heart failure (ADHF) is associated with significant morbidity and mortality but the relationship between LVEF and outcomes is unclear. We explored the association between LVEF and 30 and 180 day mortality in 7007 ADHF patients enrolled in the Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND‐HF) trial.

IMPACT OF STATINS ON LONG TERM MORTALITY IN HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)

Reduced bioavailability of nitric oxide due to endothelial dysfunction causes generation of reactive oxygen species which leads to vascular stiffness and worsening of HFpEF. Pleotropic effects of Statins beneficially modulate endothelial function by reducing inflammation, stabilizing atherosclerotic

EFFECT OF OBESITY ON MORTALITY IN PULMONARY ARTERIAL HYPERTENSION: A RETROSPECTIVE ANALYSIS

tional class (FC) I/II and III/IV. Results: Analysis was performed on a subset of 43 patients who had CAMPHOR scores and clinician assessed FC at two time points in 2009. Change in score components failed to significantly correlate with log odds and hazard rate of CW. However, in models of the baseline scores, we found evidence of a statistically significant relationship between log odds of CW and activities score (p 0.020). Cox regression results similarly indicate that there are significant associations between the risk of CW and baseline symptoms (HR 0.914, p 0.046) and activities (HR 1.2, p 0.001) scores. Similarly, ROC analysis finds that change in CAMPHOR score does not differentiate FC, whereas in follow up the symptoms score is most predictive of FC (Symptoms AUC 0.8; Activities AUC 0.76; Quality of Life AUC 0.74; Total AUC 0.78). Conclusions: Use of CAMPHOR in the clinical setting can be helpful for predicting probability and risk of hospitalization and death. The symptoms score can help the clinician assess patient FC.

TAKOTSUBO CARDIOMYOPATHY CASE SERIES – A POTENTIAL ROLE OF BETA BLOCKERS?

Since the first description of Takotsubo cardiomyopathy (TC), an increasing number of cases have been diagnosed and yet there is no known effective therapy. More precisely, Beta Blockers (BB) that have been shown to have significant benefit in heart failure have not been shown to be of benefit in